News Article | May 9, 2017
Dr. Tracey was honored for his work in immunology and neuroscience, which includes identifying the inflammatory reflex – the basis for the emerging new field of bioelectronic medicine. He was one of the first researchers to identify that stimulation of the vagus nerve, located in the neck, could reduce inflammation. Dr. Tracey's work found that the nervous system uses electrical signals to communicate information throughout the body. Virtually every cell and organ of the body is directly or indirectly controlled by these neural signals. "I am fortunate to pursue a career in research in the hope of helping patients," said Dr. Tracey. "It is an honor to be recognized by this prestigious institution that continues to have a major impact on patients and the community." Researchers at the Feinstein Institute are taking Dr. Tracey's findings and continuing to learn the language of the body's neural signals to develop devices that can monitor and treat disease and injury without the use of drugs. The Feinstein Institute for Medical Research is the research arm of Northwell Health, the largest healthcare provider in New York. Home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities, the 3,500 researchers and staff of the Feinstein are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we empower imagination and pioneer discovery, visit FeinsteinInstitute.org To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/feinstein-institute-ceo-receives-top-alumni-honor-from-boston-university-300454554.html
News Article | May 12, 2017
NEW YORK--(BUSINESS WIRE)--HealthReveal, a healthcare technology company that anticipates and mitigates adverse medical events for individuals with chronic disease, announced today a strategic investment by Northwell Ventures contributing to the Series A funding of $11.3 million. The Series A round was led by GE Ventures and joined by Greycroft Partners and Flare Capital Partners. HealthReveal partners with leading providers, payers and employers to guide patients to better health and preempt life-threatening occurrences. The company has developed a next-generation, cloud-based, decision support solution that analyzes the health of at-risk patients in real time. By using the power of evidence-based medicine and providing continual monitoring as a foundation for machine learning, health risks are detected and proactively addressed to avoid costly utilization and permanent adverse health outcomes. “We are delighted to invest in HealthReveal’s technology, which we expect will enhance their customers’ ability to combat chronic disease,” said Thomas Thornton, senior vice president and executive director of Northwell Ventures, which evaluates, develops and finances novel companies that advance Northwell’s growth and generate attractive returns. “The company brings a unique focus in deploying evidence-based medicine to assist patients and their doctors to make better and earlier decisions to optimize health.” “With Northwell as a strategic partner, we have an opportunity to ensure that incontrovertible medical knowledge is consistently and broadly applied by clinicians in providing evidence-based care,” said Dr. Lonny Reisman, the Company’s CEO and founder. “By looking at each patient personally and comprehensively we can make a meaningful improvement in clinical outcomes, medical costs and value.” HealthReveal is a healthcare technology company whose mission is to preempt the avoidable consequences of chronic disease. A fundamental component of fulfilling this mission is ensuring patients receive guideline-directed medical therapy. Patients suffering from chronic disease receive guideline-directed medical therapy only about 50% of the time1. The consequences are tragic at the individual patient level and also costly, as approximately 86% of healthcare costs per year are attributable to chronic disease2. HealthReveal partners with providers, payers and employers to continually monitor their at-risk patients and apply machine learning techniques to patient information to help avoid adverse events like strokes, heart attacks, heart failure, end stage renal disease and advanced cancer. Northwell Ventures (NV), the corporate venture arm of Northwell Health, launched a fund to invest in and actively manage companies that represent a current or future strategic interest. The NV fund seeks to identify and invest in novel technologies and business models that have the prospect to advance Northwell’s growth and generate attractive returns. The group, as a whole, works to accelerate Northwell’s broader strategic healthcare focus by utilizing Northwell as a laboratory to rapidly validate technologies, new business models, and conduct research to build profitable companies and increase the quality of care for our patients. For more information, please visit http://northwell.edu/ventures. Northwell Health is New York State’s largest health care provider and private employer, with 21 hospitals and over 550 outpatient facilities. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees – 15,000+ nurses and nearly 3,400 physicians, including nearly 2,700 members of Northwell Health Physician Partners -- are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institute. We're training the next generation of medical professionals at the visionary Hofstra Northwell School of Medicine and the School of Graduate Nursing and Physician Assistant Studies. And we offer health insurance through CareConnect. For information on our more than 100 medical specialties, visit Northwell.edu.
News Article | May 11, 2017
Cold Spring Harbor, NY - Cold Spring Harbor Laboratory (CSHL) has been awarded a research subcontract by Leidos Biomedical Research to lead a Cancer Model Development Center (CMDC) for pancreatic, breast, colorectal, lung, liver and other upper-gastrointestinal cancers. The project is 100% supported by U.S. federal funds (NCI Contract No. HHSN261201500003I, Task Order Number HHSN26100008). CSHL Cancer Center Director Dr. David Tuveson and CSHL Research Director Dr. David Spector will lead the multinational collaborative effort with Dr. Hans Clevers of the Hubrecht Institute, Dr. Aldo Scarpa and Dr. Vincenzo Corbo of the ARC-Net Centre for Applied Research on Cancer at the University of Verona, Italy, and Dr. James Crawford of Northwell Health and Dr. Peter Gregersen of Northwell's Feinstein Institute for Medical Research. The new center will generate three-dimensional organoid culture systems of cancers - next-generation models that improve upon current two-dimensional model systems used to study cancers and develop therapeutics. "CSHL is excited to lead this international team to develop more effective research models for cancer that can be shared broadly with the scientific community in order to accelerate discoveries for improved diagnosis and treatments for cancer patients," said Dr. Tuveson. Dr. Priya Sridevi from CSHL is the lead project manager for this CMDC. Under the contract, the CSHL-led CMDC will establish up to 150 organoid models in one and a half years, contributing to a larger international effort to generate 1,000 new cancer models. The Human Cancer Model Initiative (HCMI) was announced in July 2016 by the National Cancer Institute, Wellcome Trust Sanger Institute in the United Kingdom (UK), Cancer Research UK, and the foundation Hubrecht Organoid Technology. As part of NCI's Precision Medicine Initiative in Oncology, this new project is timed to take advantage of the latest cell culture and genomic sequencing techniques to create models that are representative of patient tumors and annotated with genomic and clinical information. This effort is a first step toward learning how to use these tools to design individualized treatments. Dr. Tuveson, the project's principal investigator, led an effort to develop pancreas cancer organoids, establishing CSHL as an instructional site offering courses in organoid development to the professional scientific community worldwide. Organoids can be established from healthy human tissue as well as from a variety of tumor tissue types. The power of the organoid is that it faithfully recapitulates the tissue from which it is derived. It can be genetically manipulated using technologies like shRNA (short hairpin RNA) that can turn genes on and off, or the revolutionary gene-editing tool CRISPR-Cas9. Moreover, organoid models are amenable to drug screening approaches so they can be used to validate therapeutics. The pioneer of the organoid model system, Dr. Clevers, is a key member of the new CSHL-led center. "We have laid the foundations for this collaborative program through informal exchanges of our young scientists," said Dr. Clevers. "It is very exciting that we can now turn this into a mature, well-funded endeavor that will create next-generation cancer models, as close as possible to what we find in individual patients." In support of the project, the ARC-Net team led by Dr. Scarpa and Dr. Corbo will leverage the biobanking infrastructure coordinated by Dr. Rita T. Lawlor at ARC-Net. "We are very proud to be part of this international research group," said Dr. Corbo. "This collaboration brings together world-leading expertise in cancer genomics and cancer modeling with the potential of accelerating the implementation of personalized medicine. We see an unprecedented opportunity to develop better models of cancers that will enable researchers to interrogate the wealth of genomic information available today for the rational development of cancer therapeutics." "Northwell Health and the Feinstein Institute for Medical Research are very excited to be part of this international effort, as it will help lay the foundation for new standards in clinical care that incorporate ex vivo studies of cancer tissues to guide cancer therapies," said Dr. Gregersen, Professor and Director of the Feinstein Institute's Boas Center for Genomics and Human Genetics. Dr. Crawford, Professor and Chair of the Department of Pathology and Laboratory Medicine at the Hofstra Northwell School of Medicine, noted: "Through this multi-institutional collaboration, Northwell Health will also be well-positioned to help advance the clinical trials necessary for bringing such advances into the realm of clinical care." CSHL entered into a strategic alliance with Northwell Health in April 2015, with the objective of providing CSHL researchers access to Northwell's growing network of clinical services encompassing more than 16,000 new cancer cases annually. For CSHL and Northwell Health, this CMDC project demonstrates the power of their strategic affiliation to establish closer links between research and the clinic for the benefit of cancer patients. The multinational HCMI effort aims to speed up development of new models and to make research more efficient by avoiding unnecessary duplication of scientific efforts. Genetic sequencing data from the tumors and derived models will be available to researchers, along with clinical data about the patients and their tumors. All information related to the models will be shared in a way that protects patient privacy. The goal is to give scientists around the world access to the best resources to be able to easily study all types of cancer. These new cell models could transform how we study cancer and could help to develop better treatments for patients,Scientists will make the models using tissue from patients with different types of cancer, potentially including rare and pediatric cancers, which are often under-represented or not available at all in existing cell-line collections. The new models will have the potential to reflect the biology of tumors more accurately and better represent the overall cancer patient population. The Hubrecht Institute, founded in 1916, is a research institute of the Royal Netherlands Academy of Arts and Sciences (KNAW), situated on Utrecht Science Park "The Uithof" of the largest university in the Netherlands (Utrecht). Research at the Hubrecht Institute focuses on developmental biology and stem cells at the organismal, cellular, and molecular level. A variety of biological processes are being studied, mainly concerning embryonic development and development and homeostasis of organs. Presently there are 19 research groups, including the research group of Hans Clevers, with a total of about 220 employees. Prof. Dr. Hans Clevers discovered methods to grow stem cell-derived human epithelial 'mini-organs' (organoids) from tissues of patients with various diseases including cancer. Clevers' international reputation has brought him numerous grants and prestigious awards. For more information, visit https:/ ARC-Net, Applied Research on Cancer Network, is a university research centre that was established in 2007 through a joint initiative between the University of Verona, the University Hospital Trust of Verona and the Cariverona Foundation. ARC-Net represents Italy in the International Cancer Genome Consortium where the Centre coordinates the effort of the Italian Pancreatic Cancer Genome Project to the molecular characterization of rare pancreatic tumors. ARC-Net is organized into 5 core facilities platforms, which include a cancer tissue biobank that collects biological material and associated clinical, pathological and epidemiological data. To date the biobank has material from over 5,000 consented patients and has produced over 150 patients-derived xenografts of pancreatic cancer and other cancer models. For more information, visit http://www. Northwell Health is New York State's largest health care provider and private employer, with 21 hospitals and over 550 outpatient facilities. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees - 15,000+ nurses and nearly 3,400 physicians, including nearly 2,700 members of Northwell Health Physician Partners -- are working to change health care for the better. We're making breakthroughs in medicine at the Feinstein Institute. We're training the next generation of medical professionals at the visionary Hofstra Northwell School of Medicine and the School of Graduate Nursing and Physician Assistant Studies. And we offer health insurance through CareConnect. For information on our more than 100 medical specialties, visit Northwell.edu. Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL has been a National Cancer Institute designated Cancer Center since 1987. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. The Meetings & Courses Program hosts more than 12,000 scientists from around the world each year on its campuses in Long Island and in Suzhou, China. The Laboratory's education arm also includes an academic publishing house, a graduate school and programs for middle and high school students and teachers. For more information, visit http://www.
News Article | May 15, 2017
MANHASSET, N.Y., May 15, 2017 /PRNewswire-USNewswire/ -- Lior Brimberg, PhD, assistant professor at Northwell Health's Feinstein Institute for Medical Research, received the Young Investigator Award from the International Society of Autism Research (INSAR) for her innovative work in helping to identify the causes of Autism. The award was presented at the International Meeting for Autism Research (IMFAR) in San-Francisco, CA. The INSAR's Young Investigator Award recognizes the best Autism-related empirical research studies conducted by up-and-coming scientists who received their PhD or MD in the past seven years and whose papers were published or in press during 2016. Dr. Brimberg's paper titled, "Caspr2-reactive Antibody Cloned from a Mother of an ASD Child Mediates an ASD-like Phenotype in Mice," co-authored by Dr. Brimberg and Simone Mader, PhD, postdoctoral fellow at the Feinstein Institute, found that exposure to a mother's brain-reactive antibodies while the fetus is in the womb could lead to a higher risk for developing an Autism Spectrum Disorder (ASD), particularly in males. These findings could lead to potential diagnostic and preventative strategies for Autism.
News Article | May 22, 2017
AWSM was created to highlight opportunities and collaboration among female scientists at the Feinstein Institute. AWSM comprises female faculty members who lead programs in basic, translational and clinical research. The four core initiatives of AWSM are in the areas of career development, recognition, advocacy and education, networking and mentoring. "Through the work that was started only seven years ago, we have changed how women help each other and work together at the Feinstein Institute and in science," said Nadeen Chahine, PhD, president of AWSM. "Our mantra, 'women helping women,' has eliminated barriers of progress and raised the spirits of women scientists at the Institute, but more importantly, it has elevated the level of science and discovery that we are achieving." Donors contributed more than $225,000 for awards that were distributed during the lunch to female scientists of all professional or training levels. Each award, ranging from $1,500 to $25,000, recognized scientific excellence, innovation, mentorship, education and/or training. Some of the scientists honored at this event include: Sun Jung Kim, PhD – Winner of the 2017 Barbara Hrbek Zucker Scientific Achievement Award Recognized for her work: Genetic alterations of immune system cells in lupus Jeannine Villella, DO – Winner of the 2017 Katz Institute for Women's Health Partners Council Collaborative Women in Science Award Recognized for her work: Clinical trials in gynecological oncology Lior Brimberg, PhD – Winner of the 2017 Sybil Sternlieb Innovation Award In Memory of Peter Sternlieb, MD Recognized for her work: Maternal autoantibodies in Autism Spectrum Disorder Cristina D'Abramo, PhD – Winner of the 2017 Innovation Award In Memory of Anita Ross & Marian Marsh Recognized for her work: Identification of biomarkers in Alzheimer's disease Naomi Maria, PhD – Winner of the 2017 Lisa Martin Osler Society Post-Doctoral Award Recognized for promoting diversity efforts at the Feinstein Institute and her work in kidney inflammation in Lupus Caroline Smolensky – Winner of the 2017 St. Catherine's Philoptochos Girl Scout Award Selected for a summer internship in the field of biomedical engineering, Mentor: Chunyan Li, PhD Lillie Renck – Winner of the 2017 Susan Novick Girl Scout Award Selected for a summer internship in the field of autoimmunity, Mentor: Anne Davidson, MBBS The keynote was delivered by Kiran Mazumdar-Shaw, founder of India's leading biotechnology enterprise, Biocon. She discussed her struggles as a female Indian business owner in the science and medical fields – first as a fermentation specialist and now as one of the leading manufacturers of biopharmaceuticals. Ms. Mazumdar-Shaw also touched on the importance of affordable innovation, developing ways to manufacture medicines in a way that makes the cost affordable and drugs accessible to all. "A blockbuster drug," she said, "is not a drug that makes a billion dollars but is a drug that is affordable for a billion people." About the Feinstein Institute The Feinstein Institute for Medical Research is the research arm of Northwell Health, the largest healthcare provider in New York. Home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities, the 3,500 researchers and staff of the Feinstein are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we empower imagination and pioneer discovery, visit FeinsteinInstitute.org To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/feinstein-institute-recognizes-women-in-science-300461678.html
News Article | May 23, 2017
"Our collaboration with Peerbridge Health is part of our overarching strategy to introduce disruptive technologies that will help shape the future of health care delivery," said Michael Dowling, president and CEO of Northwell Health. To better understand the potential of this partnership, Peerbridge Health and Northwell conducted a clinical trial to measure the performance of the company's flagship product, the Peerbridge Cor™, a compact, lightweight, multi-channel electrocardiogram monitor. To ensure efficacy, the Peerbridge Cor was compared to other cardiovascular monitors in a clinical trial. "The trial demonstrated this technology was superior to the current Holter Monitor standard," said Nicholas Skipitaris, MD, chief of electrophysiology at Lenox Hill Hospital. "Not only did the Peerbridge Cor deliver excellent, multi-channel, analyzable data, but it delivered less motion artifact and fewer false positives, despite our patient's active New York lifestyle." "Our vision is to help consumers partner with their physicians through easily accessible remote monitoring options," said Arthur Bertolero, CEO of Peerbridge Health. "Northwell has been a strong strategic partner, sharing our passion to bring effective digital solutions to consumers and health professionals with the highest medical standard." Incidence/Cost of Cardiovascular The American Heart Association reports cardiovascular disease and stroke as the top two killers of American adults. Cardiovascular monitoring, both inside and outside medical environments, is critical for diagnosis, proper treatment, and improved outcomes. According to the US Center for Disease Control & Prevention Foundation, annual direct medical costs associated with cardiovascular diseases are projected to rise to more than $818 billion by 2030. To get ahead of the growth in patient demand, an increasing number of providers are looking for more efficient monitoring like Peerbridge to improve treatment and deliver better outcomes, which also has the potential to significantly reduce expenses. About Northwell Health Northwell Health is New York State's largest health care provider and private employer, with 22 hospitals and over 550 outpatient facilities. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees – 15,000+ nurses and nearly 3,900 physicians, including about 2,800 members of Northwell Health Physician Partners -- are working to change health care for the better. We're making breakthroughs in medicine at the Feinstein Institute. We're training the next generation of medical professionals at the visionary Hofstra Northwell School of Medicine and the School of Graduate Nursing and Physician Assistant Studies. And we offer health insurance through CareConnect. For information on our more than 100 medical specialties, visit Northwell.edu. About Peerbridge Health Headquartered in New York, NY, Peerbridge Health, Inc. (PBH) is a venture capital backed Health IT and wearable technology company. PBH seeks to improve remote monitoring through thoughtful design and a seamless user experience. The company's current focus is to bring a new freedom and precision to remote cardiac monitoring with its initial product release scheduled for 2017. The company has two digital health and fitness pioneering patents for medical grade monitoring of all vital signs; 7,979,111 and 9,101,264, with other patents pending. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/northwell-health-makes-strategic-move-into-wearable-technology-300462368.html
News Article | February 16, 2017
As a reflection of Northern Westchester Hospital’s (NWH) nursing professionalism, teamwork and superiority in patient care, NWH has achieved Magnet® recognition for the second time, announced by the Chair of the Commission on Magnet on Tuesday, January 31, 2017. The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet rigorous standards for nursing excellence. NWH achieved this recognition previously in 2012. With this credential, NWH again joins the global community of Magnet-recognized organizations. Just 448 U.S. healthcare organizations out of over 6,300 U.S. hospitals have achieved Magnet recognition. NWH is also one of nine (9) hospitals worldwide that are Planetree Designated with Distinction which means that NWH is a teaching hospital and nationally recognized leader for patient-centered care, committed to fostering patient and family engagement and creating innovative programs and services that are fundamentally attentive to the needs of patients and their families. There are currently only five (5) hospitals worldwide that are both Planetree Designated with Distinction AND Magnet recognized. “Magnet recognition provides our community with the ultimate benchmark to measure the quality of patient care,” said Lauraine Spano-Szekely, DNP, MBA, BSN, RN, Sr. Vice President Patient Care Services and Chief Nursing Officer at NWH. “Achieving Magnet recognition reinforces the culture of excellence that is a cornerstone of how we serve our community. It’s also tangible evidence of our nurses’ commitment to providing the very best quality, patient-centered care to our patients, of which we are extremely proud.” Registered Nurses at NWH are incented to obtain higher levels of education including baccalaureate preparation and certification in their specialties. Highly-qualified staff have a positive impact on patient safety. Research demonstrates that Magnet recognition provides specific benefits to health care organizations and their communities, such as: Magnet recognition is the gold standard for nursing excellence and is a factor when the public judges health care organizations. U.S. News & World Report’s annual showcase of “America’s Best Hospitals” includes Magnet recognition in its ranking criteria for quality of inpatient care. The Magnet Model provides a framework for nursing practice, research, and measurement of outcomes. Through this framework, ANCC evaluates applicants across a number of components and dimensions to gauge an organization’s nursing excellence. The foundation of this model comprises various elements deemed essential to delivering superior patient care. These include the quality of nursing leadership and coordination and collaboration across specialties, as well as processes for measuring and improving the quality and delivery of care. To achieve Magnet recognition, organizations must pass a rigorous and lengthy process that demands widespread participation from leadership and staff. This process includes an electronic application, written patient care documentation, an on-site visit, and a review by the Commission on Magnet Recognition. “We have achieved Magnet recognition on the heels of several other noteworthy achievements in 2016 that speak to the overarching quality of care and focus on patient and family engagement that can be found at Northern Westchester Hospital,” said Spano-Szekely. In addition to re-designation as a Planetree Designated Patient-Centered Hospital with Distinction, NWH received re-accreditation by the Joint Commission, and earned its fourth consecutive “A” Grade for Patient Safety in the fall 2016 Leapfrog Hospital Safety Grade. About Northern Westchester Hospital Northern Westchester Hospital (NWH), a member of the Northwell Health, provides quality, patient-centered care that is close to home through a unique combination of medical expertise, leading-edge technology, and a commitment to humanity. Over 650 highly-skilled physicians, state-of-the-art technology and professional staff of caregivers are all in place to ensure that you and your family receive treatment in a caring, respectful and nurturing environment. NWH has established extensive internal quality measurements that surpass the standards defined by the Centers for Medicare & Medicaid Services (CMS) and the Hospital Quality Alliance (HQA) National Hospital Quality Measures. Our high-quality standards help to ensure that the treatment you receive at NWH is among the best in the nation. For more information, please visit http://www.nwhc.net and connect with us on Facebook. About Northwell Health Northwell Health is New York State’s largest health care provider and private employer, with 21 hospitals and over 550 outpatient facilities. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees – 15,000+ nurses and nearly 3,400 physicians, including nearly 2,700 members of Northwell Health Physician Partners -- are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institute. We're training the next generation of medical professionals at the visionary Hofstra Northwell School of Medicine and the School of Graduate Nursing and Physician Assistant Studies. And we offer health insurance through CareConnect. For information on our more than 100 medical specialties, visit Northwell.edu. About ANCC’s Magnet Recognition Program The Magnet Recognition Program — administered by the American Nurses Credentialing Center, the largest and most prominent nurses credentialing organization in the world — identifies health care organizations that provide the very best in nursing care and professionalism in nursing practice. The Magnet Recognition Program is the highest national honor for nursing excellence and provides consumers with the ultimate benchmark for measuring quality of care. For more information about the Magnet Recognition Program and current statistics, visit http://www.nursecredentialing.org/magnet.
News Article | February 21, 2017
NEW YORK, Feb. 21, 2017 /PRNewswire-USNewswire/ -- Northwell Health's Feinstein Institute for Medical Research today announced a strategic alliance with GE Ventures to support the Feinstein's Center for Bioelectronic Medicine (CBEM). With this investment, the Feinstein Institute will...
News Article | March 1, 2017
On Sunday, April 17, more than 500 walkers are expected to support Pediatric Cancer Foundation (PCF) at its 23rd Annual Give Hope Walk in Riverside Park. Every year more than 12,000 infants and children are diagnosed with cancer. The 5K Walk is happening to help shine a light on children and teenagers living with cancer and raise funds for scientific research. The NYC Give Hope Walk is one of many fundraisers sponsored by Mamaroneck-based Pediatric Cancer Foundation. WABC-TV meteorologist Jeff Smith will be the event’s emcee. “The goal of our walk is to help raise awareness and much needed funds to fight childhood cancers,” explains Bonnie Shyer, President of the Board of Directors. “More than 2,300 children will die each year from cancer, the causes of which are still unknown, and our funding helps critical research to attack this issue.” “Hundreds of thousands of dollars have been raised over Give Hope Walk’s 23 year history,” said PCF’s Chairman of the Board, Cheryl Rosen. “We are delighted with registration thus far and know it’s going to have a huge impact on children and youth, from birth-21, who are on the front lines of the disease, and the brilliant medical minds who are the soldiers in their fight,” she added. Some of the day’s festivities include a performance by American Idol Season 14 Finalist and cancer survivor, JAX, demonstrations by the Z100 Street Team, a “guest appearance” by Ralphie the Cockapoo and a special ribbon-cutting ceremony with Westchester pediatric cancer survivors. What started out as a grassroots organization has now become a nationally-recognized nonprofit. With the inclusion of advanced technological equipment that the organization supports, PCF-funded doctors are in communication with hospitals both nationally as well as on an international level. PCF has grown to include support for children and their families afflicted with all types of cancer. More than four decades of support has enabled the foundation to purchase state-of-the-art equipment, support research projects and bring exceptional fellows to both the surgical and oncology departments. About PCF Pediatric Cancer Foundation’s mission is to find a cure for childhood cancer. Founded in 1970, this 501(c) (3) non-profit charity raises money for research, state of the art equipment/ instruments and patient/parent care for world renowned doctors at the hospitals PCF supports. These hospitals include: Columbia University Medical Center, NewYork-Presbyterian Morgan Stanley Children’s Hospital; Comer Children’s Hospital, University of Chicago; Feinstein Institute of Medical Research - Northwell Health; Maria Fareri Children’s Hospital; Memorial Sloan Kettering Cancer Center; and The Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders at NYU Langone Medical Center. The Walkathon begins at 10:00am on Sunday, April 16 at the W. 79th Boat Basin Rotunda in Riverside Park. To register online, please visit pcfwalk.org/register/ or contact Nancy Joselson at 914-777-3127.
Tracey K.J.,Feinstein Institute
Cell | Year: 2016
Simple reflex circuits provide crucial infrastructure for the neurological control of organ systems - even the immune system. Now, Gabanyi et al. reveal a reflex mechanism in gut activated by the presence of pathogens that forces macrophages into a tissue protective phenotype. © 2016 Elsevier Inc.